

Larry Hogan, Governor · Boyd K. Rutherford, Lt. Governor · Dennis R. Schrader, Secretary

June 22, 2021

Maryland Cigarette Restitution Fund Cancer Prevention, Education, Screening and Treatment Program

Colorectal Cancer Medical Advisory Committee

Stanley Watkins, MD - Chairman Hematologist/Oncologist

Marshall S. Bedine, MD Assistant Professor of Medicine, Gastroenterology The Johns Hopkins University School of Medicine

> Douglas D. Dykman, MD Gastroenterologist

Francis Giardiello, MD Professor of Medicine The Johns Hopkins University School of Medicine

Bruce Greenwald, MD

Professor of Medicine, Gastroenterology University of Maryland School of Medicine

Elizabeth Montgomery, MD

Professor of Pathology and Vice Chair, Anatomic Pathology University of Miami Miller School of Medicine Formerly Professor of Pathology, Oncology and Orthopedic Surgery at the Johns Hopkins University School of Medicine

Ernest Tsao, MD Chief, Division of Gastroenterology MedStar Harbor Hospital

Harris Yfantis, MD Chief, Anatomic Pathology Baltimore Veterans Affairs Medical Center

Dear Participating Provider:

Thank you for participating in the Maryland Cigarette Restitution Fund Cancer Prevention, Education, Screening and Treatment (CRF CPEST) Program to provide no-cost colorectal cancer screening. The CRF CPEST Program was established to reduce cancer incidence and mortality in Maryland. As colorectal cancer is one of the seven targeted cancers under the CRF CPEST Program, the Colorectal Cancer Program seeks to increase colorectal cancer screening rates among uninsured or underinsured, low-income individuals statewide and, in some instances, to also provide diagnostic and treatment services. When further diagnostic or treatment services for eligible clients screened through CRF CPEST Program are not available, clients will be linked to appropriate programs for funding.

We are pleased to enclose the updated and newly revised "Minimal Clinical Elements for Colorectal Cancer Detection and Diagnosis." The updates include:

- Update to age of average risk individuals to *begin screening at age 45 years old* to align with United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network's (NCCN) recommendations.
- Update to definition of increased risk criteria for enrollment into the colorectal cancer screening module of personal history of precancerous polyps:
 - Precancerous polyps, as listed: adenoma, sessile serrated polyp (SSP), >5 hyperplastic polyps proximal to rectum, polyps <u>>10 mm</u>
- Update to definition of increased risk criteria for enrollment into the colorectal cancer screening module of family history:
 - First-degree relative (e.g., parent, sibling, son or daughter) diagnosed with colorectal cancer at any age, or with advanced adenomas (i.e., high grade dysplasia, <u>>1</u> cm, villous or tubulovillous histology) or with unknown pathology

- Addition of increased risk criteria for enrollment into the colorectal cancer screening module due to family history of "More than one second-degree relative (e.g., grandparent, aunt, uncle) diagnosed with colorectal cancer at age <50 years or multiple second-degree relatives diagnosed with colorectal cancer at any age."
- Update to recommended colorectal cancer screening methods:
 - Colonoscopy (preferred)
 - High Sensitive Fecal Immunochemical Test (FIT)
 - o FIT-DNA Test (i.e., Cologuard)
 - **CT Colonography:** *Prior authorization is required from the CRF CPEST Program*
- Removed Attachment 1A: Initial Screening and Attachment 1B: Recall and Surveillance Intervals and added the following algorithms for attachments, with the titles:
 - **Attachment 1A:** Guidance for Individuals of Average Risk: Recommended Screenings
 - **Attachment 1B:** Guidance for Individuals of Average or Increased Risk: Screening Requiring Prior Authorization
 - Attachment 2A: Guidance for Individuals of Increased Risk: Personal History or Current Finding of Precancerous Polyps
 - **Attachment 2B:** Guidance for Individuals of Increased Risk: Personal History or Current Finding of Colorectal Cancer
 - Attachment 2C: Guidance for Individuals of Increased Risk: Personal History of Inflammatory Bowel Disease (IBD) - Crohn's Disease or Ulcerative Colitis
 - Attachment 2D: Guidance for Individuals of Increased Risk: Personal History of Ovarian or Endometrial Cancer
 <50 Years Old or Radiation Therapy to Colon or Rectum
 - **Attachment 2E:** Guidance for Individuals of Increased Risk: Family History of Colorectal Cancer (CRC)
 - Attachment 2F: Guidance for Individuals of Increased Risk: Personal or Family History of Hereditary Non-Polyposis Colon Cancer (HNPCC/Lynch Syndrome) or Familial Adenomatous Polyposis (FAP)

We appreciate your cooperation in using the new guidelines during your care of CRF CPEST clients. If you have any questions regarding the new "Minimal Clinical Elements for Colorectal Cancer Detection and Diagnosis" for the Maryland CRF CPEST Program, please contact Ken Lin Tai, M.D., M.P.H., Director of the Center for Cancer Prevention and Control (CCPC) at 410-767-2036 or kenlin.tai@maryland.gov.

Sincerely,

Chairman, Medical Advisory Committee

Enclosure

 Ken Lin Tai, MD, MPH, Director, Center for Cancer Prevention and Control Erica Smith, MS, Deputy Director, Center for Cancer Prevention and Control Sandy Bauer, MAS, Program Manager, Cancer Screening Programs Unit JoAnn Johnston, BSN, RN, Programs Nurse Consultant, Cancer Screening Programs Unit Srishti Singh, MSN/Ed., RN, Programs Nurse Consultant, Cancer Screening Programs Unit Local CRF CPEST Coordinators

June 2021

Goal: The goal of the Minimal Clinical Elements for Colorectal Cancer Screening is to provide clients of the Maryland Cigarette Restitution Fund Cancer Prevention, Education, Screening and Treatment (CRF CPEST) Program with optimal care during colorectal cancer detection and diagnosis.

Objective: To provide clinical guidelines for colorectal cancer screening and diagnostic testing, including the interpretation and management of results.

Section	<u>1</u>	Page
I.	Risk Assessment for Colorectal Cancer Screening	
	A. Individuals Asymptomatic for Colorectal Cancer	2
	B. Individuals Symptomatic for Colorectal Cancer	3
II.	Notes on Screening Procedures	3
III.	Results and Reporting	
	A. Colonoscopy or Flexible Sigmoidoscopy	4
	B. Fecal Immunochemical Test (FIT) or Fit-DNA (i.e., Cologuard)	5
IV.	Management of Screening Findings	5
V.	Additional Screening, Diagnostic and Treatment Procedures and Program Coverage	6
Refer	ences for Recommendations	6
List of	f Colorectal Cancer Medical Advisory Committee Members	7
Attacl	hment 1A: Guidance for Individuals of Average Risk: <i>Recommended Screenings</i>	

	0
Attachment 1B:	Guidance for Individuals of Average or Increased Risk: Screening Requiring Prior
	Authorization
Attachment 2A:	Guidance for Individuals of Increased Risk: Personal History or Current Finding of
	Precancerous Polyps
Attachment 2B:	Guidance for Individuals of Increased Risk: Personal History or Current Finding of

- Attachment 2B: Guidance for Individuals of Increased Risk: Personal History or Current Finding of Colorectal Cancer
- Attachment 2C: Guidance for Individuals of Increased Risk: Personal History of Inflammatory Bowel Disease (IBD) - Crohn's Disease or Ulcerative Colitis
- Attachment 2D:Guidance for Individuals of Increased Risk: Personal History of Ovarian or
Endometrial Cancer <50 Years Old or Radiation Therapy to Colon or Rectum</th>
- Attachment 2E: Guidance for Individuals of Increased Risk: *Family History of Colorectal Cancer* (*CRC*)
- Attachment 2F: Guidance for Individuals of Increased Risk: Personal or Family History of Hereditary Non-Polyposis Colon Cancer (HNPCC/Lynch Syndrome) or Familial Adenomatous Polyposis (FAP)

June 2021

- I. Risk Assessment for Colorectal Cancer Screening: An individual that meets the criteria listed below will be enrolled in the CRF CPEST Colorectal Cancer Screening Module for colorectal cancer screening.
 - A. Individuals Asymptomatic for Colorectal Cancer

RISK CATEGORY				
AVERAGE RISK	INCREASED RISK			
Negative personal and family history, as listed under the "Increased Risk" category to the right	 Personal history of: Colorectal cancer Precancerous polyps, as listed: adenoma, sessile serrated polyp (SSP)¹, >5 hyperplastic polyps proximal to rectum, polyps ≥10 mm Inflammatory Bowel Disease (IBD), specifically: Ulcerative colitis Crohn's disease Ovarian or endometrial cancer (diagnosed at <50 years of age) or pelvic radiation Polyp of unknown pathology Family history of: First-degree relative (e.g., parent, sibling, son or daughter) diagnosed with colorectal cancer at any age, or with advanced adenomas (i.e., high grade dysplasia, ≥1 cm, villous or tubulovillous histology) or with unknown pathology More than one second-degree relative (e.g., grandparent, aunt, uncle) diagnosed with colorectal cancer at any age Personal or family history of: A high-risk syndrome (e.g., Lynch syndrome, polyposis syndromes) 			
RECOMMENI	DED SCREENING AGE			
 Begin screening at age 45 years Individuals ages 76-85 years may be screened, if the provider recommends screening after taking into account comorbidities, longevity and past colorectal cancer screening results 	• Age of individuals allowed to enroll in the program is dependent on risk category and prior findings <i>Note: Individuals age <18 years are not eligible for enrollment into the CRF CPEST Program</i>			
	D SCREENING METHOD			
 <i>Refer to Attachment 1A</i> Colonoscopy (preferred) High Sensitive Fecal Immunochemical Test (FIT) FIT-DNA Test (i.e., Cologuard); <i>see page 3, section II, letter F</i> CT Colonography: <i>Prior authorization is required from the CRF CPEST Program</i> 	 Screen with a colonoscopy at an age and on a schedule depending on risk category and prior findings: <i>Refer to the appropriate Attachment 2A, 2B, 2C, 2D, 2E or 2F</i> CT Colonography: <i>Prior authorization is required from the CRF CPEST Program</i> 			

¹ The terms sessile serrated polyp (SSP), sessile serrated adenoma (SSA) and sessile serrated lesion (SSL) are used synonymously in this document. Page 2 of 16

June 2021

B. Individuals Symptomatic for Colorectal Cancer

Regardless of risk category or screening schedule, a program-eligible individual that meets the criteria listed below will be enrolled in the CRF CPEST Colorectal Cancer Screening Program to be evaluated by a healthcare provider to determine if the client should be referred for testing to rule out colorectal cancer.

Any individual \geq 18 years old with signs/symptoms suggestive of colorectal cancer, including:

- Bleeding from rectum or blood in stool
- Change in bowel habits including 'penciling' of stools (narrowing of stool caliber)
- Microcytic (iron deficiency) anemia not explained by another condition (e.g., menstruation, blood donation)
- Unexplained abdominal mass
- Unexplained new onset of abdominal cramps or pain
- Unexplained/unintentional weight loss

II. Notes on Screening Procedures

- **A.** Each positive FIT needs to be followed up with a colonoscopy to complete the screening. An in-office FIT using stool from the digital rectal exam is NOT recommended.
- **B.** The colonoscopy is the gold standard for colorectal cancer screening. The colonoscopy is not only a screening/diagnostic tool, but it is also a preventive procedure when precancerous lesions are identified and removed.
- C. A digital rectal exam should be performed at the time of colonoscopy or sigmoidoscopy.
- **D.** The goal during a colonoscopy is that <u>all</u> lesions identified as polyps or cancer are excised, sent for pathologic diagnosis and managed based on findings. The pathology findings influence the individual's risk category for colorectal cancer, the individual's family members' risk and the interval for the recall screening.

The only exceptions to a complete removal of polyps/lesions is:

- Bleeding from rectum or blood in stool
- If the lesion is too large for excision:
 - Biopsy the lesion(s) and send for pathology
- When numerous (>20) small polyps are encountered:
 - Remove all polyps $\geq 10 \text{ mm}$
 - Remove, if possible, all polyps 5 mm 9 mm
 - Remove at least half the polyps <5 mm
 - Send all removed polyps to pathology
 - If numerous polyps are found, consider referral for genetic testing.
- **E.** Tattoo incomplete or piecemeal polypectomy, or polypectomy of large sessile polyps/hyperplastic polyps or suspected cancer for later identification.
- **F.** Reserve the FIT-DNA Test (i.e., Cologuard) for screening asymptomatic average risk clients for case-bycase situations (i.e., colonoscopy not medically indicated or a colonoscopy is offered and refused) AND only after a High Sensitive Fecal Immunochemical Test (FIT) has been offered and refused.
- **G.** Reserve a CT Colonography for case-by-case situations (i.e., anticoagulation, colonoscopy not medically indicated, inability of the colonoscopy to reach the cecum) where patient and provider discuss and determine that a CT Colonography is indicated for the individual. *Note: Prior authorization is required from the CRF CPEST Program.*
- **H.** There is insufficient evidence to recommend capsule colonoscopy as a screening test. The Colorectal Cancer Medical Advisory Committee will continue to review emerging technologies.

June 2021

III. Results and Reporting (for purposes of the CRF CPEST Program):

A. COLONOSCOPY or FLEXIBLE SIGMOIDOSCOPY

- **1.** Colonoscopy/Flexible Sigmoidoscopy Report: According to *The Quality Assurance Task Group* and *The Multi-Society Task Force Colorectal Cancer*, the endoscopic report should be structured to include the following information:
 - Patient demographics and history
 - $\circ~$ Assessment of patient risk and comorbidity
 - **Procedure indication(s)**
 - Procedure: technical description
 - **Exam Adequacy:** An "adequate" colonoscopy exam is defined as <u>reaching the cecum</u> AND <u>having bowel preparation sufficient to visualize polyps >5mm</u>.
 - Extent of examination: Actual extent of examination (anatomic segment: e.g., cecum, ascending colon, hepatic flexure)
 - \Box If cecum is not reached, provide reason
 - Bowel preparation quality
 - \Box Adequate to detect polyps >5 mm
 - \Box Inadequate to detect polyps >5 mm
 - **Retroflexion in rectum** (yes/no)
 - Technical performance
 - Examination not technically difficult
 - Examination difficult, explain
 - Length of time of withdrawal
 - Endoscopic findings should be reported using the recommendation of *The Quality Assurance Task Group* and *The Multi-Society Task Force – Colorectal Cancer*, to include the following:
 - If malignancy is suspected
 - Mass, colonic polyp(s) or submucosal lesion(s):
 - □ Anatomic location
 - □ Amount
 - \Box Size (in mm)
 - □ Bleeding/non-bleeding
 - □ Morphology
 - Flat (only slightly raised above surrounding mucosa, with or without a central depression), pedunculated or sessile
 - □ Method of removal or biopsy
 - Snare with or without cautery (saline solution injection yes/no)
 - Cold or hot biopsy
 - Fulguration or ablation with cautery
 - □ Completely removed (yes/no)
 - □ Retrieved (yes/no)
 - \Box Sent to pathology (yes/no)
 - \Box Tattoo (if done)

• Mucosal abnormality

- □ Suspected diagnosis: e.g., ulcerative colitis, Crohn's disease, ischemia, infection
- □ Anatomic location/extent
- □ Pathology obtained (yes/no)
- Other findings
- Assessment (based on history, symptoms and endoscopic findings)

June 2021

- Interventions/Unplanned events: describe events and unplanned interventions during or immediately after endoscopic procedure
- **Recommendation for date of next colonoscopy or other tests** (based on the adequacy of the colonoscopy, the optical findings, the results of pathology and the client's risk category)

2. Pathologist Report:

- **Specimens classification:** normal, polyp, carcinoma or other finding (specify).
 - A polyp or lesion should be classified by:
 - □ **Type:**
 - Adenoma: tubular adenoma, tubulovillous adenoma, villous adenoma
 - Serrated polyp or lesion: sessile serrated polyp/adenoma/lesion, traditional serrated adenoma, sessile serrated polyp/adenoma/lesion with dysplasia (mixed adenoma/hyperplastic polyp)
 - Hyperplastic polyp
 - Other polyp: e.g., mucosal polyp, inflammatory, pseudopolyp, submucosal polyp (variety of lesions), lipoma, well-differentiated neuroendocrine (carcinoid) tumor, lymphoma, metastatic tumor
 - \Box Dysplasia:
 - Whether high grade dysplasia (including severe dysplasia, carcinoma in situ and intramucosal carcinoma) is present in a conventional adenoma
 - Whether any dysplasia is present in a sessile serrated polyp/adenoma/lesion
 - □ **Presence of involvement of stalk/margin:** If neoplasia is present, determine whether the stalk or margin of the specimen is free of involvement
 - An **invasive carcinoma** should be classified as follows:

□ Differentiation (well, moderately or poorly differentiated)

- □ If carcinoma is arising in adenomatous polyp:
 - Presence or absence of lymphatic/vascular invasion
 - Margins: note whether the margin is involved; distance of the carcinoma from the margin/stalk, or distance of the carcinoma from the cauterized margin of the specimen, depth of invasion measured from the base of the muscularis mucosae.

B. FECAL IMMUNOCHEMICAL TEST (FIT) or FIT-DNA (i.e., Cologuard)

1. Results

- Positive = one or more test is positive for fecal blood
- Negative = each test in the kit is negative for fecal blood

IV. Management of Screening Findings

- **A.** Each polypectomy or biopsy noted on the colonoscopy report is matched to a specific histologic diagnosis on the pathology report.
- **B.** Timing interval of surveillance recall is based on risk category and prior findings.
- C. For individuals of Average Risk, refer to Attachment 1A or Attachment 1B
- **D.** For individuals of **Increased Risk**, see below to review appropriate attachment.
 - o Personal History or Current Finding of Precancerous Polyps- Attachment 2A
 - o Personal History or Current Finding of Colorectal Cancer- Attachment 2B
 - Personal History of Inflammatory Bowel Disease (IBD)- Attachment 2C
 - Personal History of Ovarian or Endometrial Cancer <50 Years Old or Radiation Therapy to Colon or Rectum- Attachment 2D
 - Family History of Colorectal Cancer (CRC)- Attachment 2E
 - Personal or Family History of Hereditary Non-Polyposis Colon Cancer (HNPCC/Lynch Syndrome) or Familial Adenomatous Polyposis (FAP)- Attachment 2F

June 2021

V. Additional Screening, Diagnostic and Treatment Procedures and Program Coverage

As CRF CPEST program is a safety net program, reimbursement is based on client eligibility, MDH Colorectal Cancer Minimal Clinical Elements and availability of local CRF CPEST Program funds.

Only follow-up and recall procedures that follow the MDH Minimal Clinical Elements recommendations or have been pre-authorized by MDH, will be eligible to receive reimbursement by the CRF CPEST Program.

Based on the findings on colonoscopy or other evaluation, further diagnostic testing and/or treatment may be recommended by the medical care provider(s). Clients requiring further diagnostic testing and/or treatment that is not covered by the CRF CPEST Program may need to be linked to other funding sources.

Note: Providers should consult with the local CRF CPEST Program for questions about coverage for payment of procedures.

References for Recommendations:

Final Update Summary: Colorectal Cancer: Screening. U.S. Preventive Services Task Force, 2021. <u>https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening</u> (Accessed: May 18, 2021).

NCCN Clinical Practical Guidelines in Oncology, (NCCN Guidelines ®, pg. CSCR-1): Colorectal Cancer Screening, Version 2.2021-April 13, 2021. <u>https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf</u> (Accessed: May 18, 2021).

American Cancer Society. Guideline for Colorectal Cancer Screening. Last revised November 17, 2020. Available at: <u>https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html</u> (Accessed: December 1, 2020).

Dekker, E., Bleijenberg, A. and Balaguer, F. (2020) 'Update on the World Health Organization Criteria for Diagnosis of Serrated Polyposis Syndrome', *Gastroenterology (00165085)*, 158(6), pp. 1520–1523. Available at: <u>https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=edo&AN=142911451&site=eds-live</u> (Accessed: December 1, 2020).

East JE, Atkin WS and Bateman AC (2017) 'British Society of Gastroenterology position statement on serrated polyps in the colon and rectum', *Gut*, (7), p. 1181. Available at: <u>https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=edsghw&AN=edsgcl.506260245&site=ed</u> s-live (Accessed: December 1, 2020).

Lieberman, D. *et al.* (2007) 'Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable', *Gastrointestinal Endoscopy*, 65(6), pp. 757–766. Available at:

https://search.ebscohost.com/login.aspx?direct=true&AuthType=shib&db=edo&AN=24861004&site=eds-live (Accessed: December 1, 2020)

Recommendations from the Maryland Colorectal Cancer Medical Advisory Committee, 2021 or prior years.

June 2021

Colorectal Cancer Medical Advisory Committee

The following members participated in the formulation of the Minimal Clinical Elements for Colorectal Cancer Screening:

Stanley Watkins, MD - Chairman

Hematologist/Oncologist

Marshall S. Bedine, MD

Assistant Professor of Medicine, Gastroenterology The Johns Hopkins University School of Medicine

Douglas D. Dykman, MD

Gastroenterologist

Francis Giardiello, MD

Professor of Medicine The Johns Hopkins University School of Medicine

Bruce Greenwald, MD

University of Maryland School of Medicine Professor of Medicine, Gastroenterology

Elizabeth A. Montgomery, MD

Professor of Pathology and Vice Chair, Anatomic Pathology University of Miami Miller School of Medicine Formerly Professor of Pathology, Oncology and Orthopedic Surgery at the Johns Hopkins University School of Medicine

Ernest Tsao, MD

Chief, Division of Gastroenterology MedStar Harbor Hospital

Harris Yfantis, MD


Chief, Anatomic Pathology Baltimore Veterans Affairs Medical Center

Staff from Maryland Department of Health Center for Cancer Prevention and Control:

Ken Lin Tai, MD, MPH, Director, Center for Cancer Prevention and Control
Cindy Domingo, Program Manager, CRF CPEST Program
JoAnn Johnston, RN, BSN, Program Nurse Consultant, CRF CPEST Program
Holly Harshbarger, RN, BS, Medical Services Reviewing Nurse, Breast and Cervical Cancer Diagnosis and Treatment Program

Intentionally left blank

ATTACHMENT 1A- GUIDANCE FOR INDIVIDUALS OF AVERAGE RISK: RECOMMENDED SCREENINGS




¹ If the colonoscopy exam is <u>incomplete</u> (*inability to reach cecum*), consider another screening modality to complete the screening, as soon as reasonably possible. If the colonoscopy exam is <u>inadequate</u> due to *an inadequate prep* (*unable to visualize polyps >5mm*):

[•] For individuals who are symptomatic of CRC or are currently at increased risk: repeat colonoscopy as soon as reasonably possible

[•] For those that remain average risk: repeat colonoscopy within the year

² If incomplete or piecemeal polypectomy, OR polypectomy of large (>10mm) serrated polyps, OR polyps suspect for colorectal cancer, **ink lesion** for later identification and **repeat colonoscopy within 2-6 months**

ATTACHMENT 1B- GUIDANCE FOR INDIVIDUALS OF AVERAGE OR INCREASED RISK: SCREENING REQUIRING PRIOR AUTHORIZATION



¹CT Colonography algorithm is based on the NCCN Guidelines Version 1.2019: Colorectal Cancer Screening Algorithm, CSCR-3

ATTACHMENT 2A- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: PERSONAL HISTORY OR CURRENT FINDING OF PRECANCEROUS POLYPS

FINDINGS AT COLONOSCOPY^{1, 2} **RECALL/SURVEILLANCE** Least Advanced • No Polyps **Repeat colonoscopy** • Hyperplastic polyp(s) in rectum <10mm between 5-10 vrs. • <5 Hyperplastic polyps(s) proximal to rectum <10mm • 1-2 tubular adenomas <10mm Intermediate • Polyp(s) with unknown pathology **Repeat colonoscopy in** • >5 Hyperplastic polyp(s) proximal to rectum <10mm no more than 5 yrs. • Sessile serrated polyp(s) without dysplasia <10mm Most Advanced • Hyperplastic polyp(s) anywhere in the colon >10mm • Sessile serrated polyp(s) >10 mm² or traditional serrated adenoma(s) **Repeat colonoscopy in** • Sessile serrated polyp(s) with dysplasia or adenoma(s) with high-grade dysplasia no more than 3 vrs. • 3-10 tubular adenomas <10mm \bullet >10 adenomatous polyps, any size or histology • Villous or tubulovillous histology Serrated Polyposis Syndrome (SPS) **Colonoscopy every** • >5 histologically confirmed serrated lesions/polyps proximal to the rectum, all being >5 mm in size, with >2 being 6-12 months >10mm in size *Note: These clients are* • >20 serrated lesions/polyps of any size distributed throughout the large colon, with >5 being proximal to the best referred to a rectum center with experience *Note:* Any histological subtype of serrated lesion/polyp (hyperplastic polyp, sessile serrated lesion with or without in the management of dysplasia, traditional serrated adenomas, and unclassified serrated adenoma) is included in the final polyp count. The the syndrome polyp count is cumulative over multiple colonoscopies. Malignant polyp/lesion/mass² **Refer to Attachment 2B**

¹If the colonoscopy exam is <u>incomplete</u> (inability to reach cecum), consider another screening modality to complete the screening, as soon as reasonably possible.


If the colonoscopy exam is <u>inadequate</u> due to an inadequate prep (unable to visualize polyps >5mm), repeat colonoscopy as soon as reasonably possibly

² If incomplete or piecemeal polypectomy OR polypectomy of large (≥10mm) sessile serrated polyps OR polyps suspect for colorectal cancer, **ink lesion** for later identification and **repeat colonoscopy** within 2-6 months. *Note:* The terms sessile serrated polyp (SSP), sessile serrated adenoma (SSA) and sessile serrated lesion (SSL) are used synonymously in this document.

ATTACHMENT 2B- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: PERSONAL HISTORY OR CURRENT FINDING OF COLORECTAL CANCER

FINDINGS AT COLONOSCOPY

RECALL/SURVEILLANCE



Rectal cancer: In addition to the above, consider **endoscopic ultrasound** or **flexible sigmoidoscopy at 3-6 month intervals for the first 2 yrs. after resection**

Anal, neuroendocrine lesions (carcinoid), cloacogenic carcinoma, rectal squamous cell, or other nonadenocarcinomas of colon or

¹If the colonoscopy exam is <u>incomplete</u> (*inability to reach cecum*), consider another screening modality to complete the screening, as soon as reasonably possible.

If the colonoscopy exam is **<u>inadequate</u>** due to *an inadequate prep* (*unable to visualize polyps* >5mm), **repeat colonoscopy as soon as reasonably possibly**

² If incomplete or piecemeal polypectomy OR polypectomy of large (≥ 10 mm) sessile serrated polyp or hyperplastic polyp, **ink lesion** for later identification & **repeat colonoscopy within 2-6 months.**

³ Shorter intervals may be indicated based on findings or on patient's age, family history or tumor testing indicating possible HNPCC/Lynch Syndrome.

ATTACHMENT 2C- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: PERSONAL HISTORY OF INFLAMMATORY BOWEL DISEASE (IBD) (Crohn's Disease or Ulcerative Colitis)


PERSONAL HISTORY CRITERIA	RECOMMENDED SCREENING	SURVEILLANCE/RECALL ²
Inflammatory Bowel Disease (IBD) (Ulcerative Colitis or Crohn's Disease)	All individuals ages ≥18 yrs. old with a personal history of Inflammatory Bowel Disease should be offered a screening colonoscopy ¹ 8 to 10 years after onset of disease symptoms	It is recommended that follow-up of findings and recall for colorectal cancer screening be based on the current NCCN Guidelines for Colorectal Cancer Screening for individuals with a personal history of inflammatory bowel disease ³

¹ If the colonoscopy exam is **incomplete** (*inability to reach cecum*), consider another screening modality to complete the screening, **as soon as reasonably possible.**

If the colonoscopy exam is **inadequate** due to an inadequate prep (unable to visualize polyps >5mm), repeat colonoscopy as soon as reasonably possibly ² The CRF CPEST Program does not fund colonoscopies for the sake of IBD surveillance. The CRF CPEST Program is a colorectal cancer screening program.

³ The NCCN Guidelines for Colorectal Cancer Screening can be found at <u>https://www.nccn.org/professionals/physician_gls/default.aspx#colorectal_screening</u>

ATTACHMENT 2D- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: PERSONAL HISTORY OF OVARIAN OR ENDOMETRIAL CANCER <50 YEARS OLD or RADIATION THERAPY TO COLON OR RECTUM




¹ If the colonoscopy exam is <u>incomplete</u> (*inability to reach cecum*), consider another screening modality to complete the screening, as soon as reasonably possible.

If the colonoscopy exam is <u>inadequate</u> due to an inadequate prep (unable to visualize polyps >5mm), repeat colonoscopy as soon as reasonably possibly

 $^{^{2}}$ Multiple (2 or more) negative colonoscopies may support stepwise lengthening in the colonoscopy interval.

ATTACHMENT 2E- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: FAMILY HISTORY OF COLORECTAL CANCER (CRC)




¹ If the colonoscopy exam is <u>incomplete</u> (inability to reach cecum), consider another screening modality to complete the CRC screening, as soon as reasonably possible.

If the colonoscopy exam is inadequate due to an inadequate prep (unable to visualize polyps >5mm), repeat colonoscopy as soon as reasonably possibly.

² Multiple (2 or more) negative colonoscopies may support stepwise lengthening in the colonoscopy interval.

ATTACHMENT 2F- GUIDANCE FOR INDIVIDUALS OF INCREASED RISK: PERSONAL OR FAMILY HISTORY OF HEREDITARY NON-POLYPOSIS COLON CANCER (HNPCC/LYNCH SYNDROME) OR

FAMILIAL ADENOMATOUS POLYPOSIS (FAP)



¹ If the colonoscopy exam is <u>incomplete</u> (*inability to reach cecum*), consider another screening modality to complete the screening, as soon as reasonably possible. If the colonoscopy exam is **inadequate** due to *an inadequate prep* (*unable to visualize polyps >5mm*), repeat colonoscopy as soon as reasonably possible